Literature DB >> 26307134

Docetaxel Resistance in Prostate Cancer: Taking It Up a Notch.

Tian Zhang1, Andrew J Armstrong2.   

Abstract

Notch signaling is implicated in prostate cancer progression and docetaxel resistance. Cui and colleagues describe the additive efficacy and mechanisms of a γ-secretase inhibitor, PF-03084014, and docetaxel in preclinical models of prostate cancer, suggesting the need for further clinical development of Notch pathway modulators in men with metastatic prostate cancer. ©2015 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26307134     DOI： 10.1158/1078-0432.CCR-15-1613

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  3 in total

1.  The necessity for in vivo functional analysis in human medical genetics.

Authors:  Anita M Quintana
Journal:  Med Res Arch       Date:  2015-11

2.  Synergistic Activity with NOTCH Inhibition and Androgen Ablation in ERG-Positive Prostate Cancer Cells.

Authors:  Ahmed A Mohamed; Shyh-Han Tan; Charles P Xavier; Shilpa Katta; Wei Huang; Lakshmi Ravindranath; Muhammad Jamal; Hua Li; Meera Srivastava; Eri S Srivatsan; Taduru L Sreenath; David G McLeod; Alagarsamy Srinivasan; Gyorgy Petrovics; Albert Dobi; Shiv Srivastava
Journal:  Mol Cancer Res       Date:  2017-06-12       Impact factor: 5.852

3.  Dual tumor suppressing and promoting function of Notch1 signaling in human prostate cancer.

Authors:  Karine Lefort; Paola Ostano; Maurizia Mello-Grand; Valérie Calpini; Maria Scatolini; Antonella Farsetti; G Paolo Dotto; Giovanna Chiorino
Journal:  Oncotarget       Date:  2016-07-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.